Search

Your search keyword '"Mo, Xiao-Dong"' showing total 791 results
Start Over Author "Mo, Xiao-Dong"
791 results on '"Mo, Xiao-Dong"'

2. A multifactorial risk scoring system for the prediction of early relapse in CMML patients with allo-HSCT: a nationwide representative multicenter study

Author

Zhou, Jian-Ying, Chen, Yu-Xiu, Yuan, Hai-Long, Xu, Ya-Jing, Huang, Xiao-Bing, Gao, Su-Jun, Zhang, Yi-Cheng, Zhou, Fang, Song, Xian-Min, Luo, Yi, Yang, Jian-Min, Li, Yu-Hua, Wang, Shun-Qing, Dong, Yu-Jun, Zhang, Xi, Feng, Yi-Mei, Du, Xin, Zhu, Han, Zhu, Zun-Min, Bi, Ke-Hong, Jiang, Ming, Niu, Ting, Wan, Ding-Ming, Chen, Yi, Liu, Li, Yi, Hai, Chen, Yu-Hong, Wang, Feng-Rong, Zhang, Yuan-Yuan, Mo, Xiao-Dong, Han, Wei, Wang, Jing-Zhi, Wang, Yu, Chen, Huan, Zhao, Xiang-Yu, Chang, Ying-Jun, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2024
Full Text
View/download PDF

4. Pre-transplant disease burden rather than age or donor type was associated with survival of hematopoietic cell transplantation for elderly patients with acute myeloid leukemia

Author

Ma, Rui, Liao, Yi, Zhang, Xiao-Hui, Xu, Lan-Ping, Wang, Yu, Mo, Xiao-Dong, LV, Meng, Zhang, Yuan-Yuan, Yan, Chen-Hua, Chen, Yu-Hong, Chen, Yao, Wang, Jing-Zhi, Wang, Feng-Rong, Han, Ting-Ting, Jun-Kong, Wang, Zhi-Dong, Han, Wei, Chen, Huan, He, Yun, Xu, Zheng-Li, Zheng, Feng-Mei, Fu, Hai-Xia, Liu, Kai-Yan, Huang, Xiao-Jun, and Sun, Yu-Qian

Published
2025
Full Text
View/download PDF

6. Clinical characteristics of membranous nephropathy after allogeneic hematopoietic stem cell transplantation: A real-world multicenter study

Author

Jin, Yue, Zhao, Peng, Zhang, Yuan-Yuan, Ye, Yi-Shan, Zhou, Fang, Wan, Ding-Ming, Chen, Yi, Zhou, Jian, Li, Xin, Wang, Yan, Liu, Yue, Bian, Zhi-Lei, Yang, Kai-Qian, Li, Zhen, Zhang, Jian, Xu, Wen-Wei, Zhou, Jian-Ying, An, Zhuo-Yu, Fu, Hai-Xia, Chen, Yu-Hong, Chen, Qi, Wu, Jin, Wang, Jing-Zhi, Mo, Xiao-Dong, Chen, Huan, Chen, Yao, Wang, Yu, Chang, Ying-Jun, Huang, He, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2024
Full Text
View/download PDF

9. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience

Author

Ma, Rui, Zhu, Dan-Ping, Zhang, Xiao-Hui, Xu, Lan-Ping, Wang, Yu, Mo, Xiao-Dong, Lv, Meng, Zhang, Yuan-Yuan, Cheng, Yi-Fei, Yan, Chen-Hua, Chen, Yu-Hong, Chen, Yao, Wang, Jing-Zhi, Wang, Feng-Rong, Han, Ting-Ting, Kong, Jun, Wang, Zhi-Dong, Han, Wei, Chen, Huan, Chang, Ying-Jun, He, Yun, Xu, Zheng-Li, Zheng, Feng-Mei, Fu, Hai-Xia, Liu, Kai-Yan, Huang, Xiao-Jun, and Sun, Yu-Qian

Published
2024
Full Text
View/download PDF

11. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation

Author

Huang, Qiu-Sha, Han, Tian-Xiao, Chen, Qi, Wu, Jin, Zhao, Peng, Wu, Ye-Jun, He, Yun, Zhu, Xiao-Lu, Fu, Hai-Xia, Wang, Feng-Rong, Zhang, Yuan-Yuan, Mo, Xiao-Dong, Han, Wei, Yan, Chen-Hua, Wang, Jing-Zhi, Chen, Huan, Chen, Yu-Hong, Han, Ting-Ting, Lv, Meng, Chen, Yao, Wang, Yu, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2024
Full Text
View/download PDF

12. Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (KMT2A) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation

Author

Deng, Dao-Xing, Ma, Xiao-Hang, Wu, Ze-Hua, Zhang, Xiao-Hui, Xu, Lan-Ping, Wang, Yu, Yan, Chen-Hua, Chen, Huan, Chen, Yu-Hong, Han, Wei, Wang, Feng-Rong, Wang, Jing-Zhi, Huang, Xiao-Jun, Zhao, Xiao-Su, and Mo, Xiao-Dong

Published
2024
Full Text
View/download PDF

13. Clinical characteristics and risk stratification for late-onset herpes zoster following allogeneic hematopoietic stem cell transplantation

Author

Feng, Cheng-Jie, Zhao, Peng, Fu, Hai-Xia, Yan, Chen-Hua, Wang, Chen-Cong, Zhu, Xiao-Lu, He, Yun, Wang, Feng-Rong, Zhang, Yuan-Yuan, Mo, Xiao-Dong, Kong, Yuan, Han, Wei, Wang, Jing-Zhi, Wang, Yu, Chen, Huan, Chen, Yu-Hong, Zhao, Xiang-Yu, Chang, Ying-Jun, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2024
Full Text
View/download PDF

18. Treatment of minimal residual disease in myeloid malignancies after allo-HSCT with venetoclax-based regimens in patients ineligible for or failed in the immunotherapy.

Author

Yu, Wen-Jing, Kong, Jun, Zheng, Feng-Mei, Mo, Xiao-Dong, Zhang, Xiao-Hui, Xu, Lan-Ping, Zhang, Yuan-Yuan, Sun, Yu-Qian, Jin, Jian, Huang, Xiao-Jun, and Wang, Yu

Subjects
HEMATOPOIETIC stem cell transplantation, GRAFT versus host disease, TREATMENT failure, PATIENT safety, MYELOID cells
Abstract

Background: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological analysis can be identified by the minimal residual disease (MRD) monitoring. The most used first-line regimens for MRD are immunotherapies. However, for patients who were ineligible for or failed in first-line immunotherapies, options were limited. Methods: A total of 20 patients with myeloid malignancies with recurrent MRD after allo-HSCT were included in this study. The safety and efficacy of venetoclax-based regimens were analyzed. Results: There were 13 patients (65%) treated with venetoclax combined with hypomethylating agents concomitantly and seven patients (35%) treated with venetoclax monotherapy. After venetoclax-based regimens, MRD was eliminated in 11 patients (55%) with 6 subsequently developing recurrent MRD and 5 remaining in molecular remission. MRD declined in two patients (10%), and no responses in seven patients (35%). Among the two patients with declined MRD, one patient finally eliminated MRD after two cycles of the venetoclax-based regimen, and the other patient's MRD further declined after the second regimen. The objective response rate (ORR) was 65%. The median duration of response was 103 (12–313) days. The incidences of grades 3–4 neutropenia, anemia, and thrombocytopenia independently of pretreatment status were 30%, 20% and 20%, respectively. Conclusion: Venetoclax-based regimens are efficient and safe for MRD in patients with myeloid malignancies ineligible for or failed in the first-line immunotherapies after allo-HSCT. Plain language summary: What is the context?: Relapse was the major cause of treatment failure in patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients who still suffer from the disease while cannot be detected by morphological analysis can be identified by the minimal residual disease (MRD) monitoring. The most used first-line regimens for MRD are immunotherapies. For patients who were ineligible for or failed in first-line immunotherapies, options were limited. What is new?: A total of 20 patients with myeloid malignancies with recurrent MRD after allo-HSCT were included in this study. The safety and efficacy of venetoclax-based regimens were analyzed. ⮚ Venetoclax-based regimens are efficient for MRD in patients with myeloid malignancies ineligible for or failed in the first-line immunotherapies after allo-HSCT. ⮚ After venetoclax-based regimens, MRD was eliminated in 11 patients (55%), and five patients were still MRD eliminated at the time of this writing or until death. ⮚ MRD declined in two patients (10%), and no responses in seven patients (35%). Among the two patients with declined MRD, one patient finally eliminated MRD after two cycles of the venetoclax-based regimen, and the other patient's MRD further declined after the second regimen. ⮚ The objective response rate (ORR) was 65%. ⮚ The median duration of response was 103 (12-313) days. Venetoclax-based regimens are safe for MRD in patients with myeloid malignancies ineligible for or failed in the first-line immunotherapies after allo-HSCT. ⮚ The incidences of grades 3–4 neutropenia, anemia, and thrombocytopenia independently of pretreatment status were 30%, 20% and 20%, respectively. What is the impact? This study provides evidence that in the context of preemptive treatment for post-transplant MRD, venetoclax-based regimens may be a choice in patients who were ineligible for or failed in the first-line immunotherapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.

Author

Lv, Meng, Yan, Chen‐Hua, Ma, Rui, He, Yun, Zhang, Yuan‐Yuan, Wang, Zhi‐Dong, Chen, Yu‐Hong, Han, Wei, Kong, Jun, Han, Ting‐Ting, Liu, Jing, Zheng, Hao, Mo, Xiao‐Dong, Sun, Yu‐Qian, Wang, Yu, Xu, Lan‐Ping, Zhang, Xiao‐Hui, and Huang, Xiao‐Jun

Subjects
ACUTE myeloid leukemia, CELL transplantation, GRAFT versus host disease, MULTIVARIATE analysis, DECITABINE, STEM cell transplantation, HEMATOPOIETIC stem cell transplantation
Abstract

Summary: Patients with relapsed/refractory acute myeloid leukaemia (R/R AML), especially those who failed in novel target agents are related to dismal survival. We developed a multi‐institutional, single‐arm, prospective phase II trial, to investigate intensified conditioning with 'Mega‐Dose' decitabine (MegaDAC) following allogeneic haematopoietic cell transplantation (allo‐HCT) for R/R AML. From 2019 to 2023, 70 heavily treated R/R AML patients in active disease were consecutively enrolled. Significantly, every patient (n = 18) harbouring specific mutations exhibited no response to their best available target agents (BATs). Moreover, 74.3% of the enrolled patients did not reach remission following venetoclax‐based regimens. All patients underwent intravenous decitabine (400 mg/m2) along with busulfan and cyclophosphamide. Median follow‐up was 26 months (8–65) after HCT. All engrafted patients achieved MRD negativity post‐HCT, with a median 3.3‐log reduction in recurrent genetic abnormalities. The regimen was well tolerated, without irreversible grades III–IV toxicity peri‐engraftment. The estimated 2‐year CIR was 29.6% (18.4%–41.7%) and the est‐2‐year NRM was 15.5% (7.8%–25.5%). The est‐2‐year LFS, OS, and GRFS were 55.0% (43.5%–69.4%), 58.6% (47.0%–73.0%), and 42.9% (31.9%–57.6%), respectively. Multivariate analysis showed that pre‐HCT drug exposures had no significant impact on primary outcomes. MegaDAC is highlighted as an effective and safe option for R/R AML in the new era of targeted therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Pretransplantation risk factors for MRD after allogeneic stem cell transplantation in AML patients: A prospective study

Author

Chang, Ying-Jun, primary, Li, Si-Qi, additional, Yu, Chunzi, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Zhang, Xiao-hui, additional, Chen, Huan, additional, Chen, Yuhong, additional, Wang, Fengr-Rong, additional, Sun, Yuqian, additional, Yan, Chen-Hua, additional, Lv, Meng, additional, Mo, Xiao-Dong, additional, Liu, Yanrong, additional, Liu, Kaiyan, additional, Zhao, Xiaosu, additional, Zhao, Xiang-Yu, additional, and Huang, Xiaojun, additional

Published
2024
Full Text
View/download PDF

28. A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy

Author

Zhao, Peng, Wu, Ye-jun, He, Yun, Chong, Shan, Qu, Qing-yuan, Deng, Rui-xin, Sun, Xiao-wan, Huang, Qiu-sha, Liu, Xiao, Zhu, Xiao-lu, Wang, Feng-rong, Zhang, Yuan-yuan, Mo, Xiao-dong, Han, Wei, Wang, Jing-zhi, Wang, Yu, Chen, Huan, Chen, Yu-hong, Zhao, Xiang-yu, Chang, Ying-jun, Xu, Lan-ping, Liu, Kai-yan, Huang, Xiao-jun, and Zhang, Xiao-hui

Published
2021
Full Text
View/download PDF

29. Prognostic Factors and Outcomes in Patients With Septic Shock After Allogeneic Hematopoietic Stem Cell Transplantation

Author

Huang, Qiu-Sha, Han, Tian-Xiao, Fu, Hai-Xia, Meng, Han, Zhao, Peng, Wu, Ye-Jun, He, Yun, Zhu, Xiao-Lu, Wang, Feng-Rong, Zhang, Yuan-Yuan, Mo, Xiao-Dong, Han, Wei, Yan, Chen-Hua, Wang, Jing-Zhi, Chen, Huan, Chen, Yu-Hong, Han, Ting-Ting, Lv, Meng, Chen, Yao, Wang, Yu, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2024
Full Text
View/download PDF

34. Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia

Author

Wang, Zhi-dong, Wang, Yue-wen, Xu, Lan-ping, Zhang, Xiao-hui, Wang, Yu, Chen, Huan, Chen, Yu-hong, Wang, Feng-rong, Han, Wei, Sun, Yu-qian, Yan, Chen-hua, Tang, Fei-fei, Mo, Xiao-dong, Wang, Ya-zhe, Liu, Yan-rong, Liu, Kai-yan, Huang, Xiao-jun, and Chang, Ying-jun

Published
2021
Full Text
View/download PDF

37. Distinct Immune Homeostasis Remodeling Patterns after HLA‐Matched and Haploidentical Transplantation.

Author

Guo, Huidong, Guo, Liping, Wang, Bixia, Jiang, Xinya, Wu, Zhigui, Mo, Xiao‐Dong, Sun, Yu‐Qian, Zhang, Yuan‐Yuan, Wang, Zhi‐Dong, Kong, Jun, Yan, Chen‐Hua, and Huang, Xiao‐Jun

Subjects
HEMATOPOIETIC stem cell transplantation, IMMUNOLOGICAL tolerance, TRANSGENIC mice, FLOW cytometry, IMMUNE system, T cells
Abstract

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a widely used treatment for a variety of hematopoietic disorders, and also provides a valuable platform for investigating the development of donor‐derived immune cells in recipients post‐HSCT. The immune system remodels from the donor to the recipient during allo‐HSCT. However, little is known about the cell profile alterations as donor homeostasis rebalances to recipient homeostasis following HSCT. Here, multi‐omics technology is applied at both the single cell and bulk sample levels, as well as spectrum flow cytometry and fluorescent transgenic mouse models, to dissect the dynamics of the rebalanced homeostatic immune system in recipients after allo‐HSCT. The data reveal that all immune subpopulations observed in donors are successfully restored in recipients, though with varying levels of abundance. The remodeling of immune homeostasis exhibits different patterns in HLA‐matched and haploidentical HSCT, highlighting distinct biases in T cell reconstitution from the central and peripheral pathways. Furthermore, ZNF683 is critical for maintaining the persistence and quiescence of CD8 T‐cell in haploidentical HSCT. The research can serve as a foundation for developing novel strategies to induce immune tolerance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation.

Author

Wu, Jin, He, Yu‐Chen, Huang, Qiu‐Sha, He, Yun, Zhao, Peng, Chen, Qi, Zhu, Xiao‐Lu, Fu, Hai‐Xia, Kong, Jun, Wang, Feng‐Rong, Zhang, Yuan‐Yuan, Mo, Xiao‐Dong, Yan, Chen‐Hua, Lv, Meng, Wang, Yu, Xu, Lan‐Ping, Liu, Kai‐Yan, Huang, Xiao‐Jun, and Zhang, Xiao‐Hui

Subjects
HEMATOPOIETIC stem cell transplantation, RECEIVER operating characteristic curves, PROGNOSTIC models, MAGNETIC resonance imaging, GLASGOW Coma Scale, VIRAL encephalitis
Abstract

Summary: The objective of this study was to identify independent prognostic factors of viral encephalitis (VE) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) and establish a prognostic model to identify post‐transplant VE patients with a greater likelihood of mortality. Among 5380 patients in our centre from 2014 to 2022, 211 patients who developed VE after allo‐HSCT were reviewed in this retrospective study. Prognostic factors were selected, and a prognostic model was constructed using Cox regression analysis. The model was subsequently validated and estimated using the area under the receiver operating characteristic curve (AUC), a calibration plot and decision curve analysis (DCA). Glasgow Coma Scale score <9, lesions >3 lobes on magnetic resonance imaging and severe thrombocytopenia were identified as independent prognostic risk factors for VE patients who underwent allo‐HSCT. The prognostic model GTM (GTM is an abbreviation for a model composed of three risk factors: GCS score <9, severe thrombocytopenia [platelet count <20 000 per microliter], and lesions >3 lobes on MRI) was established according to the regression coefficients. The validated internal AUC was 0.862 (95% confidence interval [CI], 0.773–0.950), and the external AUC was 0.815 (95% CI, 0.708–0.922), indicating strong discriminatory ability. Furthermore, we constructed calibration plots that demonstrated good consistency between the predicted outcomes and the observed outcomes. DCA exhibited high accuracy in this system, leading to potential benefits for patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Author

Chen, Yu-Hong, Zhang, Xian, Cheng, Yi-Fei, Chen, Huan, Mo, Xiao-Dong, Yan, Chen-Hua, Chen, Yao, Han, Wei, Sun, Yu-Qian, Wang, Yu, Zhang, Xiao-Hui, Xu, Lan-Ping, Liu, Kai-Yan, Yang, Junfang, Zhang, Jianping, Zhang, Gai-Ling, Shi, Yanze, Su, Yun-Chao, Li, Wen-Qian, Xu, Li, Song, Dan, Zhang, Min, Lu, Peihua, and Huang, Xiao-Jun

Published
2020
Full Text
View/download PDF

40. Outcomes of symptomatic venous thromboembolism after haploidentical donor hematopoietic stem cell transplantation and comparison with human leukocyte antigen-identical sibling transplantation

Author

Zhang, Gao-Chao, Zhang, Yuan-Yuan, Zeng, Qiao-Zhu, Meng, Xing-Ye, Zhao, Peng, Fu, Hai-Xia, He, Yun, Zhu, Xiao-Lu, Mo, Xiao-Dong, Wang, Jing-Zhi, Yan, Chen-hua, Wang, Feng-Rong, Chen, Huan, Chen, Yao, Han, Wei, Wang, Yu, Xu, Lan-Ping, Liu, Kai-Yan, Huang, Xiao-Jun, and Zhang, Xiao-Hui

Published
2020
Full Text
View/download PDF

45. Clinical characteristics of membranous nephropathy after allogeneic hematopoietic stem cell transplantation: a real-world multicenter study

Author

Jin, Yue, primary, Zhao, Peng, additional, Zhang, Yuan-Yuan, additional, Ye, Yi-Shan, additional, Zhou, Fang, additional, Wan, Ding-Ming, additional, Chen, Yi, additional, Zhou, Jian, additional, Li, Xin, additional, Wang, Yan, additional, Liu, Yue, additional, Bian, Zhi-Lei, additional, Yang, Kai-Qian, additional, Li, Zhen, additional, Zhang, Jian, additional, Xu, Wen-Wei, additional, Zhou, Jian-Ying, additional, An, Zhuo-Yu, additional, Fu, Hai-Xia, additional, Chen, Yu-Hong, additional, Chen, Qi, additional, Wu, Jin, additional, Wang, Jing-Zhi, additional, Mo, Xiao-Dong, additional, Chen, Huan, additional, Chen, Yao, additional, Wang, Yu, additional, Chang, Ying-Jun, additional, Huang, He, additional, Huang, Xiao-Jun, additional, and Zhang, Xiao-Hui, additional

Published
2024
Full Text
View/download PDF

46. Clinical Impact of BK Viremia during Haploidentical Stem Cell Transplantation and Its Association with Hemorrhagic Cystitis

Author

Xu, Lan-Ping, primary, Chen, Yao, additional, Zhao, Xiaosu, additional, Chen, Huan, additional, Lv, Meng, additional, Fu, Haixia, additional, Chen, Yuhong, additional, Wang, Feng-Rong, additional, Jingzhi, Wang, additional, Yan, Chen-Hua, additional, Zhang, Yuan-Yuan, additional, Mo, Xiao-Dong, additional, Zhang, Xiaohui, additional, Wang, Yu, additional, and Huang, XiaoJun, additional

Published
2024
Full Text
View/download PDF

47. Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment

Author

Cheng, Cong, primary, Deng, Dao-Xing, additional, Zhang, Xiao-Hui, additional, Xu, Lan-Ping, additional, Wang, Yu, additional, Yan, Chen-Hua, additional, Chen, Huan, additional, Chen, Yu-Hong, additional, Han, Wei, additional, Wang, Feng-Rong, additional, Wang, Jing-Zhi, additional, Sun, Yu-Qian, additional, Huang, Xiao-Jun, additional, and Mo, Xiao-Dong, additional

Published
2024
Full Text
View/download PDF

48. Incidence, risk factors and impact on transplant outcomes of cytokine release syndrome after infusion of haploidentical stem cells with anti-thymocyte globulin

Author

Wang, Yu, primary, Zheng, Feng-Mei, additional, Kong, Jun, additional, Jingzhi, Wang, additional, zhidong, wang, additional, Wang, Fengr-Rong, additional, Han, Tingting, additional, Fu, Haixia, additional, han, wei, additional, Zhang, Yuan-Yuan, additional, Yan, Chen-Hua, additional, Chen, Huan, additional, Chen, Yao, additional, Chen, Yuhong, additional, Mo, Xiao-Dong, additional, Lv, Meng, additional, Sun, Yuqian, additional, Yifei, Cheng, additional, Xu, Lan-Ping, additional, Zhang, Xiao-hui, additional, Liu, Kaiyan, additional, and Huang, Xiaojun, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results